Personalised medicine through individual approaches to resolve lung injury

B. Patel (London, United Kingdom)

Source: Virtual Congress 2021 – Acute respiratory distress syndrome phenotypes: implications for diagnosis and treatment

Session: Acute respiratory distress syndrome phenotypes: implications for diagnosis and treatment
Session type: Symposium
Number: 218

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
B. Patel (London, United Kingdom). Personalised medicine through individual approaches to resolve lung injury. Virtual Congress 2021 – Acute respiratory distress syndrome phenotypes: implications for diagnosis and treatment

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Personalised medicine in interstitial lung diseases Source: Eur Respir Rev, 27 (148) 170117; 10.1183/16000617.0117-2017 Year: 2018
Personalised medicine through ventilator settings: implications of lung morphology in ARDS Source: Virtual Congress 2021 – Acute respiratory distress syndrome phenotypes: implications for diagnosis and treatment Year: 2021
Personalised targeted medicine Source: Research Seminar 2015 - Personalising respiratory care in Europe Year: 2015
Personalised medicine through biological subphenotyping of ARDS Source: Virtual Congress 2021 – Acute respiratory distress syndrome phenotypes: implications for diagnosis and treatment Year: 2021
The impact of personalised therapies on respiratory medicine Source: Eur Respir Rev 2013; 22: 72-74 Year: 2013
Contemporary challenges for specialist nursing in interstitial lung disease Source: Breathe, 14 (1) 36; 10.1183/20734735.014917 Year: 2018
Personalised medicine in asthma: from curative to preventive medicine Source: Eur Respir Rev 2017; 26: 160010 Year: 2017
Modern molecular lung cancer diagnostics – how to use and interpret it wisely Source: International Congress 2018 – PG11 Modern approaches in lung cancer diagnostics and therapy Year: 2018
The clinical benefit of personalised medicine in lung cancer Source: International Congress 2014 – Understanding the benefit of current personalised medicine platforms Year: 2014
What is evidence-based medicine? Source: Annual Congress 2006 - PG16 - The use of evidence-based medicine and practice for the clinician (jointly organised with the ACCP) Year: 2006
The future of personalised medicine in COPD Source: International Congress 2016 – Endotyping: the means to personalised medicine in lung disease Year: 2016
Personalised medicine in paediatric asthma, including from the patient's perspective Source: International Congress 2016 – PG8 Paediatric asthma Year: 2016
The contribution of evidence-based medicine Source: Annual Congress 2004 - PG17 - How to conduct a scientific survey on respiratory health Year: 2004
Current and new challenges in occupational lung diseases Source: Eur Respir Rev, 26 (146) 170080; 10.1183/16000617.0080-2017 Year: 2017
Diagnosing asthma in the era of personalised medicine: biology, physiology and imaging Source: Virtual Congress 2021 – Precision medicine in asthma and COPD Year: 2021
What kind of emphasis do we need in clinical research to enable personalised respiratory medicine? Source: Eur Respir J, 55 (1) 1901866; 10.1183/13993003.01866-2019 Year: 2020
Personalised medicine in asthma: time for action Source: Eur Respir Rev, 26 (145) 170064; 10.1183/16000617.0064-2017 Year: 2017